Validation of the graded prognostic assessment index for patients with brain metastases

Authors

  • Carsten Nieder Medical Department, Radiation Oncology Unit, Nordlandssykehuset HF, Bodø, Norway; Faculty of Medicine, University of Northern Norway, Tromsø, Norway
  • Kirsten Marienhagen Faculty of Medicine, University of Northern Norway, Tromsø, Norway
  • Hans Geinitz Department of Radiation Oncology, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany
  • Michael Molls Department of Radiation Oncology, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany

DOI:

https://doi.org/10.1080/02841860802342390

Abstract

Background. The purpose of this study is to evaluate the performance of the new “Graded Prognostic Assessment” (GPA) index, which recently was developed from data in the Radiation Therapy Oncology Group (RTOG) database, in patients with brain metastases treated outside of randomized clinical trials. Material and methods. The authors analyzed 232 patients with brain metastases and assigned these patients to the four indices previously evaluated by the RTOG (recursive partitioning analysis class, Score Index for Radiosurgery, Basic Score for Brain Metastases, and GPA). Results. The present data confirm the results of the RTOG analysis. Each of the four indices splits the data set into prognostically different groups. In the GPA groups, median survival was 10.3, 5.6, 3.5, and 1.9 months, respectively (p<0.01). In the RTOG analysis, these figures were 11.0, 6.9, 3.8, and 2.6 months, respectively. Conclusion. These results confirm the validity of the GPA index in a patient population that most likely is more representative of the normal clinical situation than patients included in randomized trials.

Downloads

Download data is not yet available.

Downloads

Published

2009-01-01

How to Cite

Nieder, C. ., Marienhagen, K. ., Geinitz, H. ., & Molls, M. . (2009). Validation of the graded prognostic assessment index for patients with brain metastases. Acta Oncologica, 48(3), 457–459. https://doi.org/10.1080/02841860802342390